{
    "clinical_study": {
        "@rank": "122769", 
        "arm_group": {
            "arm_group_label": "Spattz  3 intragastric balloon", 
            "arm_group_type": "Experimental", 
            "description": "obese patients, .\tBMI \u2265 35 kg/m\u00b2 or  BMI \u2265 30 kg/m\u00b2 and hypertension or diabetes mellitus. All will have the intragastric balloon"
        }, 
        "brief_summary": {
            "textblock": "This is an open-label trial investigating the effect of Spatz  3 intragastric balloon on\n      weight loss on obesity and associated  co- morbidities.\n\n      The study aim is to evaluate the effect of the intra gastric balloon on weight reduction and\n      on related co- morbidities during 1 year of balloon implantation and  a year following\n      explantation."
        }, 
        "brief_title": "The Long Term Effect of Adjustable Spaatz 3 Intragastric Balloon on Weight Loss", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Obesity", 
            "Diabetes", 
            "Hypertension"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Hypertension", 
                "Obesity", 
                "Weight Loss"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        - 1. Subjects willing to comply with study requirements and have signed an informed\n        consent form.\n\n        2. Age 18-70 3. BMI \u2265 35 kg/m\u00b2 or  BMI \u2265 30 kg/m\u00b2 and hypertension or diabetes mellitus 4.\n        Documented negative pregnancy test in women of childbearing potential. 5. Women of\n        childbearing potential agree to remain on contraceptives for the duration of their trial\n        participation.\n\n        Exclusion Criteria:\n\n          -  1. Subjects receiving any prescription or over the counter weight loss medication\n             within 30 days prior to randomization (including GLP-1 analogs).\n\n             2. Previous GI surgery that could preclude the ability to place the device. 3.\n             Subjects with a history of abnormal GI anatomical findings documented on imaging\n             study, which in the opinion of the investigator, may impair implantation of the IGB\n             device 4. Subjects with severe GERD that are  not responding to Proton Pump Inhibitor\n             (PPI) 5. Known abnormal pathologies or conditions of the upper gastrointestinal\n             tract.\n\n             6. Subjects with symptomatic gallstones within 6 months prior to randomization 7.\n             Coagulopathy defined as hgb <10g/dl and platelet < 100,000/ml or diagnosis of\n             hemophilia, factor X deficiencies or fibrinogen abnormalities 8. Subjects requiring\n             prescription antithrombotic therapy (i.e. anticoagulant or antiplatelet agent) 9.\n             Subjects unable to discontinue NSAIDs (non-steroidal anti-inflammatory drugs) or any\n             other drugs with bleeding as a potential side effect during the study duration.\n\n             10. Subject is or has been enrolled in another investigational study within 3 months\n             of participation into the current study 11. Subjects not residing within a 3 hour\n             driving distance of the study center."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "25", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 2, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02003872", 
            "org_study_id": "0670-13-SMC"
        }, 
        "intervention": {
            "arm_group_label": "Spattz  3 intragastric balloon", 
            "description": "Intra gastric balloon implanted using gastroscopy", 
            "intervention_name": "Spatz 3 intragastric balloon", 
            "intervention_type": "Device"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "December 22, 2013", 
        "location": {
            "contact": {
                "email": "langa@sheba.health.gov.il", 
                "last_name": "Alon Lang, MD", 
                "phone": "972-3-5302909"
            }, 
            "facility": {
                "address": {
                    "city": "Ramat Gan", 
                    "country": "Israel", 
                    "zip": "52621"
                }, 
                "name": "Sheba Medical Center"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Israel"
        }, 
        "number_of_arms": "1", 
        "official_title": "The Long Term Effect of Adjustable Spaatz 3 Intragastric Balloon on Weight Loss", 
        "overall_contact": {
            "email": "langa@sheba.health.gov.il", 
            "last_name": "Alon Lang, MD", 
            "phone": "3-5302909"
        }, 
        "overall_official": {
            "affiliation": "Sheba Medical Center", 
            "last_name": "Alon Lang, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Israel: Ministry of Health", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "May 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Excess weight loss", 
            "safety_issue": "No", 
            "time_frame": "2 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02003872"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Sheba Medical Center", 
            "investigator_full_name": "Dr. Alon Lang", 
            "investigator_title": "Senior physician GI department", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "measure": "liver fat infiltration", 
            "safety_issue": "No", 
            "time_frame": "2 years"
        }, 
        "source": "Sheba Medical Center", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Sheba Medical Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}